在泌尿系统肿瘤治疗领域，根治性膀胱切除术（Radical Cystectomy, RC）是针对浸润性尿路上皮膀胱癌（Urothelial Bladder Cancer, UBC）的重要治疗手段，而淋巴结清扫（Lymph Node Dissection, LND）作为RC的关键组成部分，其清扫范围一直是研究热点。本篇综述通过系统评价和 ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The following is a summary of “Health-related quality of life after radical cystectomy for bladder cancer in elderly patients ...

who were not receiving surgery to remove the bladder (cystectomy) and nearby lymph nodes, has been discontinued after it showed no improvement over the standard chemoradiation treatment for this ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug Administration (FDA) to treat adults with muscle-invasive bladder cancer ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as an ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

followed by Imfinzi as an adjuvant single agent post-radical cystectomy in adults with muscle-invasive bladder cancer (MIBC). The decision follows the receipt of a priority review by the agency ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...